Gemcitbine Plus Cisplatin versus Gemcitabine Plus Carboplatin in Patients with NSCLC, Stage IIIB and IV. An Internim Analysis

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023841%3A_____%2F01%3A00005650" target="_blank" >RIV/00023841:_____/01:00005650 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Gemcitbine Plus Cisplatin versus Gemcitabine Plus Carboplatin in Patients with NSCLC, Stage IIIB and IV. An Internim Analysis
Original language description
Non-samll lung cancer (NSCLC)accounts for approximately 75 - 80 % of lung cancer case. NSCLC is typically diagnosed in later stages, locoregioally advanced or metastatic and is usually inoperable. The impact of many single-agent and combinationchemotherapies on response rate and survival in NSCLc is disapointing, even thoug many of these agents are effectivein othe solid tumours. The majority of patients who develop lung cancer die of the disease. many of drugs used against NSCLC are associatwith significant toxicities. zher is a clear need for few new agentswich can achieve or surspass these response rates, with more acceptable toxicity profile. Gemcitabine is one such agent.
Czech name
—
Czech description
—

Project
<a href="/en/project/NC6070" target="_blank" >NC6070: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in non-small cell lung cancer stage IIIB and IV. A randomized study.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2001
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)